Lirafit 6 mg/ml Prefilled Pen 3 ml

Lirafit 6 mg/ml Prefilled Pen 3 ml belongs to the class of anti-diabetic drugs, primarily used to treat type 2 diabetes mellitus in the children above 10 years and adult. Diabetes mellitus is a metabolic disease that causes high blood sugar levels. Type 2 diabetes occurs when a hormone released by the pancreas to lower blood glucose called 'insulin' is secreted but unable to get utilized by our body's cell to produce energy.  

Lirafit 6 mg/ml Prefilled Pen 3 ml contains Liraglutide a recombinant Deoxyribonucleic acid (rDNA) which works by increasing insulin release from the pancreas during high blood sugar levels (after meal) and decreases the amount of sugar the liver makes. Lirafit 6 mg/ml Prefilled Pen 3 ml also slows stomach emptying time, thereby decreasing appetite and promotes weight loss in an individual. 

Some common side effects of Lirafit 6 mg/ml Prefilled Pen 3 ml include nausea, vomiting, diarrhoea, decreased appetite, stomach upset, constipation, headache, feeling tired, rash, and dizziness. These side effects are not familiar to everyone and vary individually. If you notice any side effects that are not manageable, please consult your doctor. 

Before starting Lirafit 6 mg/ml Prefilled Pen 3 ml, let your doctor know if you have any medical history of heart, kidney or liver diseases, pancreatitis (inflammation of the pancreas), and stomach disorders like gastroparesis (delayed gastric emptying). Do not take or stop this medicine, if the doctor did not advise you to do so. Do not concurrently use Lirafit 6 mg/ml Prefilled Pen 3 ml with prandial insulin (mealtime insulin). It is advised to limit your alcohol intake while using Lirafit 6 mg/ml Prefilled Pen 3 ml to avoid low blood sugar levels further. Pregnant and breastfeeding women should consult their doctor before starting Lirafit 6 mg/ml Prefilled Pen 3 ml.

Lirafit 6 mg/ml Prefilled Pen 3 ml treats type 2 diabetes mellitus and contains ‘Liraglutide’. It is a recombinant DNA (rDNA) that mimics the action of a natural hormone called Incretin (metabolic hormone, which stimulates a decrease in blood glucose levels). It works by increasing insulin release from the pancreas during high blood sugar levels (after meal) and decreases the amount of sugar the liver makes. Lirafit 6 mg/ml Prefilled Pen 3 ml may be advised with or without other medications along with diet and exercise to control blood sugar levels. 

• Nausea
• Vomiting
• Diarrhoea
• Decreased appetite
• Stomach upset
• Constipation
• Headache
• Feeling tired
• Rash
• Dizziness 

Brief your medical history if you have any heart, kidney or liver diseases, pancreatitis (inflammation of the pancreas), stomach disorders like gastroparesis (delayed gastric emptying), high cholesterol levels, gallbladder problems, and depression before starting Lirafit 6 mg/ml Prefilled Pen 3 ml. Lirafit 6 mg/ml Prefilled Pen 3 ml is contraindicated in patients with multiple endocrine neoplasia type 2 (tumours in thyroid and parathyroid glands) and personal or family history of thyroid cancer. Do not concurrently use Lirafit 6 mg/ml Prefilled Pen 3 ml with prandial insulin (mealtime insulin). If you are also using insulin, take Lirafit 6 mg/ml Prefilled Pen 3 ml and insulin injections separately. Please do not mix them. You can inject both injections in the same body region, but the injection sites should not be next to each other. Do not share an injection pen, cartridge, or syringe with another person, even if the needle is changed. It is advised to limit your alcohol intake while using Lirafit 6 mg/ml Prefilled Pen 3 ml to avoid low blood sugar levels further. Pregnant and breastfeeding women should consult their doctor before starting this medication. Lirafit 6 mg/ml Prefilled Pen 3 ml is advised to be only used in children above ten years of age and adults. 

Drug-Drug Interaction: Lirafit 6 mg/ml Prefilled Pen 3 ml may interact with other anti-diabetic medicines (insulin glargine, insulin degludec), hormones (levothyroxine), corticosteroids (prednisone), psychiatric medicines (olanzapine), antibiotics (ciprofloxacin), high blood pressure medicines (propranolol, metoprolol), and glaucoma eye drops (timolol). 

Drug-Food Interaction: Limit alcohol intake since it affects blood sugar levels. Avoid fatty foods and include healthy carbohydrates in your diet.

Drug-Disease Interaction: Tell your doctor before taking Lirafit 6 mg/ml Prefilled Pen 3 ml if you have a medical history of allergic reactions to medicines, heart, kidney or liver diseases, pancreatitis (inflammation of the pancreas), stomach disorders like gastroparesis (delayed gastric emptying), high cholesterol levels, gallbladder problems, and depression. Lirafit 6 mg/ml Prefilled Pen 3 ml is contraindicated in patients with multiple endocrine neoplasia type 2 (tumours in thyroid and parathyroid glands) and personal or family history of thyroid cancer.

• INSULIN GLARGINE
• INSULIN DEGLUDEC
• LEVOTHYROXINE
• PREDNISONE
• OLANZAPINE
• CIPROFLOXACIN
• PROPRANOLOL
• METOPROLOL
• TIMOLOL

• Maintain a fibre-rich diet and include healthy carbohydrates from fruits, vegetables and whole grains to maintain your blood glucose levels.
• Eat at regular intervals.
• Keep a check on your weight and exercise regularly to keep your heart healthy.
• Your doctor also guides you on noticing and managing the early symptoms of high/low blood sugar levels.
• Gastrointestinal side effects can be managed with simple modifications in your lifestyle. These include cutting down on sugars and fatty foods, avoiding carbonated drinks and foods that cause gas. 

• Lirafit 6 mg/ml Prefilled Pen 3 ml may increase the risk of developing thyroid gland tumour, including medullary thyroid carcinoma (MTC - a type of thyroid cancer). 
• Never reuse insulin needles and never share needles or insulin pens. 

Diabetes mellitus: Also known as adult-onset diabetes, is a metabolic disease that causes high blood sugar levels. It is a type 2 diabetes and occurs when the insulin (a hormone produced by the beta cells of the pancreas) is resistant in breaking the glucose to produce energy (insulin resistance) or the pancreas (an organ behind the stomach) produce little or no insulin at all. This disease mostly occurs in people aged above 40 years, but can also occur in childhood based on the risk factors. The treatment includes oral glucose-lowering medicines and insulin shots.